AR072793A1 - Compuestos de aril isoxazol con actividades antitumorales - Google Patents

Compuestos de aril isoxazol con actividades antitumorales

Info

Publication number
AR072793A1
AR072793A1 ARP090102496A ARP090102496A AR072793A1 AR 072793 A1 AR072793 A1 AR 072793A1 AR P090102496 A ARP090102496 A AR P090102496A AR P090102496 A ARP090102496 A AR P090102496A AR 072793 A1 AR072793 A1 AR 072793A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
substituted once
aryl
alkoxy
Prior art date
Application number
ARP090102496A
Other languages
English (en)
Inventor
Giuseppe Giannini
Claudio Pisano
Paolo Carminati
Daniele Simoni
Walter Cabri
Riccardo Baruchello
Original Assignee
Sigma Tau Res Switzerland Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Res Switzerland Sa filed Critical Sigma Tau Res Switzerland Sa
Publication of AR072793A1 publication Critical patent/AR072793A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de aril-isoxazol que tienen actividad antitumoral a través de la inhibicion de la proteína chaperona molecular de choque térmico 90 (Hsp90) como una posible diana biologica: Uso de aquellos compuestos médicos relacionados con el cáncer y con otras enfermedades en las que una inhibicion de la Hsp90 resulta eficaz, y la composicion farmacéutica que contiene dichos compuestos. También se proveen compuestos intermediarios de síntesis de los mismos, procesos para prepararlos y un procedimiento de preparacion de estos derivados de aril-isoxazol. Reivindicacion 1: Un compuesto de la formula general (1) donde X es halogeno. alquilo, alquenilo, haloalquilo, arilo, heteroarilo, bencilo, amino, alquilamino o aminocarbonilo; Y y Z, iguales e diferentes, son halogeno, nitro, haloalquilo, R3, OR3, amino, alquilamino o aminocarbonilo; R3 es hidrogeno o alquilo; R1 es =NHC(=D)ER4 o NR5R6; D es O o S; E es O, NR7 o está ausente; R7es hidrogeno o alquilo; R4 es alquilo opcionalmente sustituido una vez por alcoxi o amino; alquenilo, arilo opcionalmente sustituido una vez o más por alquilo, halo o heterocicloalquilalquilo, cicloalquilo opcionalmente sustituido una vez o más por alquilo, haloalquilo, alcoxi, amino o aminoalquilo; norbornilo, adamantilo, heteroarilo opcionalmente sustituido una vez o más por alquilo, alquilaminocarbanilo; heterocicloalquilo opcionalmente sustituido una vez o más por alquilo; o heterocicloalquilalquilo opcionalmente sustituido una vez o más por alquilo; R5 y R6 independientemente son hidrogeno, alquilo, cicloalquilo, heterocicloalquilo opcionalmente sustituidos una vez o más por alquilo; alquenilo, bencilo, arilo, arilalquilo opcionalmente sustituido por alcoxi; heteroarilo, heteroarilalquilo opcionalmente sustituido una vez o más por alquilo, hidroxialquilo, alcoxi, alcoxicarbonilo; o R5 y R6, juntos y con el átomo de nitrogeno al que están unidos, pueden formar un anillo heterocíclico con entre 5 y 7 miembros opcionalmente substituido, cuya sustitucion opcional es halogeno, hidroxilo, alcoxilo, alquilo, arilo, arilalquilo, alquilcarbonilo o aminocarbonilo; R2 es NR8R9; R8 y R9, iguales o diferentes son seleccionados a partir de H, alquilo opcionalmente sustituido por halogeno; haloalquilo, arilo, cicloalquilo, heterocicloalquilo y heteroarilo; o R8 y R9, juntos y con el átomo de nitrogeno al que están unidos, forman un heterociclo que puede contener uno o dos heteroátomos más seleccionados de O, S o N y que opcionalmente, pueden ser sustituidos una vez o más por alquilo o halogeno; sus tautomeros, sus isomeros geométricos, sus formas opticamente activas, como los enantiomeros, los diastereomeros y sus formas racémicas, así como sus sales derivadas farmacéuticamente aceptables. Reivindicacion 12: Un compuesto de la formula (2) donde X, Y, Z y R2 son, tal como se describe mas arriba, un intermediario en la síntesis de compuestos de acuerdo con la reivindicacion 1. Reivindicacion 14: Un compuesto de la formula (3) donde X, Y, Z y R2 son, tal como se describe más arriba, un intermediario en la síntesis de compuestos de acuerdo con la reivindicacion 1.
ARP090102496A 2008-07-04 2009-07-03 Compuestos de aril isoxazol con actividades antitumorales AR072793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08159692 2008-07-04

Publications (1)

Publication Number Publication Date
AR072793A1 true AR072793A1 (es) 2010-09-22

Family

ID=40019071

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102496A AR072793A1 (es) 2008-07-04 2009-07-03 Compuestos de aril isoxazol con actividades antitumorales

Country Status (18)

Country Link
US (1) US8383616B2 (es)
EP (1) EP2310377B1 (es)
JP (1) JP5640002B2 (es)
KR (1) KR20110050615A (es)
CN (1) CN102083804A (es)
AR (1) AR072793A1 (es)
AU (1) AU2009265745B2 (es)
BR (1) BRPI0913834A2 (es)
CA (1) CA2729710A1 (es)
EA (1) EA019793B1 (es)
IL (1) IL210200A0 (es)
MX (1) MX2010013913A (es)
MY (1) MY150604A (es)
NZ (1) NZ590861A (es)
SG (1) SG192464A1 (es)
TW (1) TWI450898B (es)
WO (1) WO2010000748A1 (es)
ZA (1) ZA201100007B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
JP2014503446A (ja) 2010-10-27 2014-02-13 ピクセリジェント・テクノロジーズ，エルエルシー ナノ結晶の合成、キャップ形成および分散
KR101275264B1 (ko) 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
CN103724269B (zh) * 2012-10-11 2016-12-21 中国科学院上海药物研究所 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途
MA39483A (fr) * 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
US9855249B2 (en) 2014-10-02 2018-01-02 Flatley Discovery Lab, Llc Isoxazole compounds and methods for the treatment of cystic fibrosis
CN104725329B (zh) * 2015-01-13 2017-01-18 陕西科技大学 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法
CN104803934B (zh) * 2015-05-04 2018-01-02 陕西科技大学 一种具有抗肿瘤活性的苯基异噁唑羧酸类化合物及其合成方法与应用
IT201700081419A1 (it) * 2017-07-18 2019-01-18 Rare Partners Srl Derivati isossazolici come induttori di emoglobina fetale in precursori eritroidi derivati da pazienti beta-talassemici
CN112367991A (zh) * 2018-06-25 2021-02-12 达纳-法伯癌症研究所股份有限公司 Taire家族激酶抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001232340A1 (en) * 2000-02-18 2001-08-27 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
ES2393483T3 (es) * 2003-02-11 2012-12-21 Vernalis (R&D) Limited Compuestos de isoxazol como inhibidores de las proteínas de choque térmico
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
GB0603880D0 (en) * 2006-02-27 2006-04-05 Novartis Ag Organic compounds
UA101950C2 (ru) * 2007-03-01 2013-05-27 Новартис Аг Соль присоединения с кислотами, гидрат и полиморфная форма этиламида 5-(2,4-дигидрокси-5-изопропилфенил)-4-(4-морфолин-4-илметилфенил)-изоксазол-3-карбоновой кислоты и композиция, которая содержит эти формы (варианты)

Also Published As

Publication number Publication date
TWI450898B (zh) 2014-09-01
AU2009265745A1 (en) 2010-01-07
NZ590861A (en) 2012-08-31
BRPI0913834A2 (pt) 2015-10-20
ZA201100007B (en) 2011-10-26
CN102083804A (zh) 2011-06-01
JP2011526594A (ja) 2011-10-13
KR20110050615A (ko) 2011-05-16
IL210200A0 (en) 2011-03-31
US8383616B2 (en) 2013-02-26
US20110245221A1 (en) 2011-10-06
EP2310377A1 (en) 2011-04-20
MY150604A (en) 2014-01-30
EP2310377B1 (en) 2015-09-16
MX2010013913A (es) 2011-03-03
AU2009265745B2 (en) 2013-07-04
JP5640002B2 (ja) 2014-12-10
CA2729710A1 (en) 2010-01-07
TW201012815A (en) 2010-04-01
EA201170139A1 (ru) 2011-08-30
WO2010000748A1 (en) 2010-01-07
SG192464A1 (en) 2013-08-30
EA019793B1 (ru) 2014-06-30

Similar Documents

Publication Publication Date Title
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20090773A1 (es) Derivados de morfolina pirimidina
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR066972A1 (es) Derivados azapeptidicos
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
UY28333A1 (es) Inhibidores de caspasa y sus usos.
PE20141000A1 (es) Ureas asimetricas y usos medicos de las mismas
ECSP088257A (es) Derivados de amida
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure